Fetalix has been granted a patent protecting its regenerative biomaterial technology for the treatment of intervertebral disc degeneration and associated low back pain. The patent represents an important milestone in the company’s development, securing intellectual property rights for key aspects of its product and supporting its continued advancement toward clinical application.
The patented technology is based on a decellularized extracellular matrix derived from fetal tissue. Designed to provide biological cues that support tissue regeneration, the biomaterial features a distinctive composition rich in specific collagen types and other extracellular matrix components. By interacting with native disc cells, the technology aims to stimulate regenerative processes within the degenerated intervertebral disc.
In addition to the biomaterial itself, the patent covers methods for its formulation and manufacture into injectable therapeutic products. These include microparticle- and hydrogel-based compositions developed for minimally invasive delivery, enabling administration directly into the affected disc tissue.
The protection of innovative technologies through patents plays a critical role in the development of regenerative medicine. Intellectual property rights provide the foundation for long-term research and development, facilitate collaborations with industrial and clinical partners, and help attract the investment required to translate scientific discoveries into therapeutic solutions.
The granting of this patent strengthens Fetalix’s position in the field of regenerative medicine.
April 28, 2026
